Retrospective Analysis of Metabolic Syndrome, Risk Factors and Therapeutic Approach: A Study among Patients of Malwa Region
DOI:
https://doi.org/10.61554/ijnrph.v1i2.2023.51Abstract
Metabolic syndrome is illustrated by the concur of several cardiovascular risk factors including insulin resistance, central obesity, visceral adiposity, atherogenic dyslipidemia and hypertension. The proposed study was conducted on 133 patients within the course of 6 months from various region of Malwa. The data was collected using patients’ diagnostic reports, prescriptions and medical history and was separately studied using Microsoft excel 2009 spread sheets. A total of 133 patients were enrolled for this study. 46.7% were already suffering from Metabolic disorder remaining 53.3% patients were at risk of it. Group II patients were detected with high level of triglyceride, uncontrolled diabetes, hypothyroidism besides stage II hypertension, ischemic heart disease and angina pectoris. In Group I T2DM, hyperthyroidism, hypertension besides acute myocardial infraction and Angina was identified. Whereas in Group III patients, angina pectoris was dormant in addition to cardiovascular diseases, ischemic heart disease and acute myocardial infraction. Antacids, antidiabetic, antihypertensive, diuretics, vitamins, statins, glucocorticoids, non-steroidal anti-inflammatory drugs were preferably prescribed medications. Certain class of medication were found to influence risk of metabolic syndrome due to their Adverse drug reaction. Delayed identification and certain Adverse drug reaction were identified by reviewing medication grids. Multi-fold domain such as genetic, behavioral, lifestyle and clinical factors also contributed in metabolic syndrome. Therefore, health care professionals, pharmacist, patients and caregivers need to collaborate and explore better behavioral, healthy lifestyle and safer medications to avoid the additional complicity and breakthrough of Metabolic syndrome.
Downloads
Metrics
Keywords:
Metabolic Syndrome, World health Organization, T2DM, Adverse drug reaction, Hypothyroidism, Crucial Diagnostic Analysis.Downloads
Published
How to Cite
Issue
Section
References
Albert MM, Eckel RH, Grundy SM. Harmonizing the MS: a joint interim statement of the international diabetes federation task force on epidemiology and prevention. National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity,” Circulation. 2009;120(16):1640-5. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Hardy DS, Racette SB, Garvin JT. Ancestry specific associations of a genetic risk score dietary patterns and MS: A longitudinal ARIC study. BMC Med Genomics Impact Factor. 2021;14:118. DOI: https://doi.org/10.1186/s12920-021-00961-8
Kaur J. Comprehensive review on MS. Cardiol Resesch Practicals. 2014:943162. DOI: https://doi.org/10.1155/2014/943162
Grundy SM, Cleeman JI, Daniels SR, DonatoKA, FranklinBA. Diagnosis and management of the MS. Circulation. 2005;112(17):2735-52. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.169404
Rochlani Y, Pothinein NV, Kovelamudi S, Mehta JL. Pathophysiology, management and modulation by natural compound. Ther Advantage CVDs. 2017;11(8):215-25. DOI: https://doi.org/10.1177/1753944717711379
Lee MK, Han K, Kim MK. Changes in MS and its components and the risk of type 2 diabetes: A nationwide cohort study. Sci Rep. 2020;10:2313. DOI: https://doi.org/10.1038/s41598-020-59203-z
Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104(25):3046-51. DOI: https://doi.org/10.1161/hc5001.100624
You CH, Lee KY, Chey WY, Menguy R. Electrogastrographic study of patients with unexplained nausea, bloating and vomiting. Gastroenterology. 1980;79(2):311-4. DOI: https://doi.org/10.1016/0016-5085(80)90147-X
Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and CVD: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA- HIT). Arch Intern Med. 2002;162(22):2597-604. DOI: https://doi.org/10.1001/archinte.162.22.2597
Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant MIsurvivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. The care investigators. Circulation. 1998;98(23):2513-9. DOI: https://doi.org/10.1161/01.CIR.98.23.2513
Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study CollaborativeGroup. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16. DOI: https://doi.org/10.1016/S0140-6736(03)13636-7
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;38:S4-S36. DOI: https://doi.org/10.2337/diacare.28.suppl_1.S4
Reaven P. Metabolic syndrome. J Insur Med. 2004;36(2):132-42. PMID 15301226. 14. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care. 1999;22(5):659-60. DOI: https://doi.org/10.2337/diacare.22.5.659
Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21(3):360-7. DOI: https://doi.org/10.2337/diacare.21.3.360
Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237-52. DOI: https://doi.org/10.4158/EP.9.S2.5
Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third national health and nutrition examination survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP – defined MS, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.13. DOI: https://doi.org/10.2337/diabetes.52.5.1210
Wilson PW, D’Agostino RB, Parise H, Sulliva L. Meigs JB. Ms Precursor CVD T2DM. Circulation. 2005;112:3066-3072.14. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.539528
Enkhmaa B, Shiwaku K, Anuurad E, Nogi A, Kitajima K, Yamasaki M, et al. Prevalence of the MS using the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians. Clin Chim Acta Int J Clin Chem. 2005;352(1-2):105-13. DOI: https://doi.org/10.1016/j.cccn.2004.08.012
Shah T, Jonnalagadda SS. Kick lighter JR, Diwan S, Hopkins BL. Prevalence of MS risk factors among young adult Asian Indians. J Immigr Health. 2005;7:117-26. DOI: https://doi.org/10.1007/s10903-005-2645-5
Shiwaku K, Nogi A, Kitajima K, Anuurad E, Enkhmaa B, Yamasaki M, et al. Prevalence of the MS using the modified ATP. J Occup Health. 2005; 47;III definitions for workers in Japan, Korea and Mongolia:126-35. DOI: https://doi.org/10.1539/joh.47.126
Choi SH, Ahn CW, Cha BS, Chung YS, Lee KW, Lee HC, et al. The prevalence of the MS in Korean adults: comparison of WHO and NCEP criteria. Yonsei Med J. 2005;46(2):198-205. DOI: https://doi.org/10.3349/ymj.2005.46.2.198
Huang PL. A comprehensive definition for MS. DMM Dis Models Mech. 2009;2 (5-6):231-7. DOI: https://doi.org/10.1242/dmm.001180
Wofford MR, King DS, Harrell TK, Wofford M, Drug-Induced MS. Drug-Induced Metabolic Syndrome. J Clin Hypertens. 2006;8(2):114-9. DOI: https://doi.org/10.1111/j.1524-6175.2006.04751.x
Verhaegen AA, Van Gaal LF. Drugs that affect body weight, body fat distribution, and metabolism. Endotext S Dartmouth (MA). 2000.
Leon BM. Diabetes and CVD: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246-58. DOI: https://doi.org/10.4239/wjd.v6.i13.1246
Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122(2):133-41. DOI: https://doi.org/10.7326/0003-4819-122-2-199501150-00010
Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993;118(7):529-39. DOI: https://doi.org/10.7326/0003-4819-118-7-199304010-00008
Altabas V. Drug. Drug treatment of metabolic syndrome. Curr Clin Pharmacol. 2013;8(3):224-31. DOI: https://doi.org/10.2174/1574884711308030009
Rask Larsen J, Dima L, Correll CU, Manu P. The pharmacological management of MS. Expert Rev Clin Pharmacol. 2018;11(4):397-410. DOI: https://doi.org/10.1080/17512433.2018.1429910
Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs. 2001;3(4):293-319. DOI: https://doi.org/10.2165/00128072-200103040-00006
Lee K, et al. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection retina 2009. DOI: https://doi.org/10.1097/IAE.0b013e3181b21056
Feingold KR, Anawalt B, Boyce A. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism [internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537590/.
